Authored By: Sarah
11 Jul 2024

 Breast Cancer Liquid Biopsy Testing Devices Market Size to grow by USD 1164 million between 2024-2028

According to a research report “ Breast Cancer Liquid Biopsy Testing Devices Market” by Type (CTCs and circulating nucleic acids, Extracellular vesicles) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1164 million, at a CAGR of almost 31.34% during the forecast period. Breast cancer, a prevalent and significant health concern globally, is responsible for increased mortality rates among populations worldwide. This disease primarily affects women, with the aging population exhibiting the highest prevalence. A mutation in the BRCA1 and BRCA2 genes, which function as tumor suppressors, is the primary cause of breast cancer. The growing geriatric population and the increasing incidence of breast cancer are driving the demand for advanced diagnostic solutions. Liquid biopsy testing devices offer a non-invasive, accurate, and cost-effective alternative to traditional diagnostic methods for breast cancer detection and monitoring. These devices provide valuable insights into the genetic makeup of cancer cells, enabling early detection and personalized treatment plans. The market for breast cancer liquid biopsy testing devices is poised for significant growth due to the increasing burden of breast cancer and the advantages offered by these technologies.

Browse market data tables, figures, and in-depth TOC on “Breast Cancer Liquid Biopsy Testing Devices Market” by Type (CTCs and circulating nucleic acids, Extracellular vesicles) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Type, the CTCs and circulating nucleic acids segment is projected to dominate the market size in 2024

ai_market_segmentation_by

By Geography, North America  segment is expected to hold the largest market size for the year 2024

In the realm of oncology diagnostics, the identification and analysis of Circulating Tumor Cells (CTCs) and circulating nucleic acids have emerged as essential tools for healthcare professionals. These biomarkers, primarily found in the circulatory system, are indicative of various cancer types, including breast, lung, prostate, and colorectal. The screening and diagnosis of these biomarkers facilitate prognostic and predictive assessments, enabling early intervention and effective treatment plans. CTCs, which originate from primary and secondary tumors, serve as representatives of the tumor and its metastases. In the context of breast cancer, CTCs are predominantly utilized for biomarker analysis, providing valuable insights into the disease's progression and potential new genetic mutations. Circulating nucleic acids, another significant finding in liquid biopsy testing, offer additional diagnostic value by providing information on genetic alterations and tumor burden.

North America is forecasted to hold the largest market size by region in 2024

The Breast Cancer Liquid Biopsy Testing Devices market represents a significant growth opportunity for businesses in the diagnostics industry. These devices enable the non-invasive detection of breast cancer through the analysis of circulating tumor cells and biomarkers in bodily fluids. Market expansion is driven by rising incidences of breast cancer, increasing demand for minimally invasive diagnostic procedures, and technological advancements in liquid biopsy testing. Companies investing in this sector can capitalize on these trends and contribute to improving patient outcomes and advancing cancer research.

The Breast Cancer Liquid Biopsy Testing Devices Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Bio Rad Laboratories Inc.
  • Cell Microsystems Inc.
  • Exact Sciences Corp.
  • F. Hoffmann La Roche Ltd.
  • Guardant Health Inc.
  • Illumina Inc.
  • Isogen Life Science BV
  • Mesa Laboratories Inc.
  • Myriad Genetics Inc.
  • Natera Inc.
  • NeoGenomics Laboratories Inc.
  • Novogene Co. Ltd.
  • OncoDNA
  • Pfizer Inc.
  • QIAGEN NV
  • SAGA Diagnostics AB
  • Sysmex Corp.
  • Thermo Fisher Scientific Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Breast Cancer Liquid Biopsy Testing market is witnessing significant growth due to the increasing demand for non-invasive procedures in the diagnosis and prognostics of breast cancer. This market includes instruments, reagent kits, services, and other offerings related to the detection of circulating biomarkers such as Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), Circulating Tumor Cells (CTCs), and Cell-free DNA (cfDNA) in breast cancer patients. Technologies such as Next-generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) are commonly used for breast cancer liquid biopsy testing. However, limitations associated with specificity and short supply of these testing devices, as well as shutdowns in molecular laboratories, pathology laboratories, health laboratories, physician laboratories, and reference laboratories, can impact market growth. Circulating biomarkers play a crucial role in personalized medicine for breast cancer patients, providing valuable information for prognostics and diagnostics. Health organizations are investing in these technologies to improve patient outcomes and reduce the need for invasive procedures. Despite the challenges, the market for breast cancer liquid biopsy testing is expected to continue growing, driven by the potential for early detection and more effective treatment options.

Market Research Overview

The Breast Cancer Liquid Biopsy Testing Devices Market is witnessing significant growth due to the increasing demand for non-invasive procedures in cancer diagnostics and treatment monitoring. Healthcare institutions and biotech companies are investing heavily in the development of liquid biopsy systems, reagent kits, and instruments for early detection and risk assessment of breast cancer. These tests, which analyze circulating biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles in blood samples, offer several advantages over traditional diagnostic methods. Liquid biopsy tests provide real-time information on the genetic makeup of tumors, enabling personalized therapeutics and treatment selection. With the growing focus on personalized medicine and healthcare reforms, these tests are becoming a revenue contributor to the medical community. However, limitations associated with specificity and sensitivity, short supply, and shutdowns pose challenges to the market. Key players in the market include Canexia Health, Biocept, Qiagen, Cancer Research, World Health Organization, and various molecular laboratories, pathology laboratories, health laboratories, physician laboratories, and reference laboratories. Technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and circulating biomarkers are driving innovation in the market. The market is expected to grow significantly in the coming years, with a focus on improving the accuracy and accessibility of liquid biopsy tests for breast cancer patients. In conclusion, the Breast Cancer Liquid Biopsy Testing Devices Market is a promising area of growth in the healthcare industry, offering non-invasive, real-time, and personalized solutions for breast cancer diagnosis and treatment monitoring. However, challenges related to specificity, sensitivity, and supply chain management need to be addressed to ensure the widespread adoption of these tests. The medical community, healthcare organizations, and biotech companies are working together to overcome these challenges and bring the benefits of liquid biopsy testing to breast cancer patients. Keywords: Breast cancer, healthcare institutions, biotech companies, treatment monitoring, cancer diagnostics, blood samples, medical community, liquid biopsy tests, specificity, sensitivity, treatment selection, early detection, healthcare reforms, personalized therapeutics, liquid biopsy systems, revenue contributor, risk assessment, prognostics, diagnostics, circulating biomarker, services, instruments, reagent kits, short supply, shutdowns, limitations associated, breast cancer liquid biopsy, next-generation sequencing, polymerase chain reaction, circulating tumor DNA, CTC, biomarkers, NGS, PCR, Canexia Health, Biocept, Qiagen, Circulating, Cancer Research, World Health Organization, Drug Administration, Lancet Oncology, molecular laboratories, pathology laboratories, health laboratories, physician laboratories, reference laboratories, extracellular vesicles, cellfree DNA, circulating tumor cells, circulating biomarkers, liquid biopsy, personalized medicine, healthcare organizations, noninvasive procedures.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio